TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04756193

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
Description: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
Description: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
Description: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
Description: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
Description: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry
Study: NCT05377554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: Bevonescein will be infused during the pre-operative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: Bevonescein will be infused during the pre-operative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: Bevonescein will be infused during the pre-operative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: Bevonescein will be infused during the pre-operative period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay
Description: Intra-operative real time nerve visualization will be undertaken using WLR with FL Overlay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay
Description: Intra-operative real time nerve visualization will be undertaken using WLR with FL Overlay.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-operative Visualization using White Light Reflectance (WLR)
Description: Intra-operative real time nerve visualization will be undertaken using WLR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-operative Visualization using White Light Reflectance (WLR)
Description: Intra-operative real time nerve visualization will be undertaken using WLR.
Study: NCT06231823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extraction
Description: Simple / surgical dental extraction for necrotic. irreversible pulpitis, unrestorable, and first permanent molars with sever molar incisor hypomineralization.
Study: NCT05087914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa (100mg/25mg):
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Study: NCT04979780

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Retrospective cohort analysis using US Optum De-Identified EHR data.

Intervention type: DRUG
Intervention: Low molecular weight heparin (LMWH)
Description: Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
Study: NCT05087914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Study: NCT04979780

Intervention type: DRUG
Intervention: Direct Oral Anticoagulants (DOAC)
Description: Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
Study: NCT05230004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFIT prosthesis
Description: An adjustable modular prosthesis that can be fit in a single session. Fully adjustable by wearer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFIT prosthesis
Description: An adjustable modular prosthesis that can be fit in a single session. Fully adjustable by wearer.
Study: NCT05087914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Study: NCT04836221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support
Description: Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension).
Study: NCT05404425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visioconference: live visual injury evaluation
Description: For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
Study: NCT06058442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NORTASE®
Description: 10-15 capsules of NORTASE® per day - over 6 months
Study: NCT04836858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMK389
Description: Active

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMK389
Description: Active

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT06437236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: Group A will receive ondansetron 4mg diluted in normal saline,The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron
Description: Group B will receive granisetron 1mg diluted in normal saline.The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block
Study: NCT04005534

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard group
Description: Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preemptive group
Description: Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
Study: NCT06113510

Intervention type: RADIATION
Intervention: Hybrid 18F-GP1 positron emission tomography and coronary computed tomography coronary angiography
Description: 18F-GP1 will be synthesized by our radiochemistry facility, the Edinburgh Imaging Facility Radiochemistry (EIFR), which is co-located within our Edinburgh Imaging Facility, Queens Medical Research Institute (EIF QMRI) using our well-established protocols. Each patient will undergo 18F-GP1 PET/CT coronary angiography imaging on our hybrid scanner (Biograph mCT, Siemens) as soon as practical after their index event and within a maximum of 7 days from symptom onset. Patients will initially be injected with 250 MBq 18F-GP1, before resting in a quiet environment for 60 min. A low-dose attenuation correction CT scan (120 kV, 50 mAs, 5/3 mm) will be followed by acquisition of PET data in list mode using a two 20-min bed position centred on the thoracic aorta and heart. A contrast-enhanced CT coronary angiogram will then be performed.

Intervention type: RADIATION
Intervention: Hybrid 18F-GP1 positron emission tomography and coronary computed tomography coronary angiography
Description: 18F-GP1 will be synthesized by our radiochemistry facility, the Edinburgh Imaging Facility Radiochemistry (EIFR), which is co-located within our Edinburgh Imaging Facility, Queens Medical Research Institute (EIF QMRI) using our well-established protocols. Each patient will undergo 18F-GP1 PET/CT coronary angiography imaging on our hybrid scanner (Biograph mCT, Siemens) as soon as practical after their index event and within a maximum of 7 days from symptom onset. Patients will initially be injected with 250 MBq 18F-GP1, before resting in a quiet environment for 60 min. A low-dose attenuation correction CT scan (120 kV, 50 mAs, 5/3 mm) will be followed by acquisition of PET data in list mode using a two 20-min bed position centred on the thoracic aorta and heart. A contrast-enhanced CT coronary angiogram will then be performed.
Study: NCT05732532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 2 mL of bupivacaine 0.5% (5 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 0.5 mL of lidocaine 1% (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 0.5 mL of dexamethasone (10 mg/mL) injected at the origin of each bilateral greater and lesser occipital nerves

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.5 mL of normal saline 0.9% injected at the origin of each bilateral greater and lesser occipital nerves

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Greater/lesser occipital nerve blocks
Description: Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater/lesser occipital nerve blocks
Description: Subjects will receive a total of 12 mL injectate divided equally between the 4 injection sites of the bilateral greater and lesser occipital nerves using the landmark-based technique.
Study: NCT06570772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT16
Description: AVT16 will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Entyvio (vedolizumab) will be given as iv infusion at Wks 0, 2, 6, 14, 22, 30, 38 and 46
Study: NCT05292534

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid amplification
Description: Hearing aid will be fit to prescribed participant hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid amplification with an added sound
Description: Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated.
Study: NCT06424847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (physical activity and diet)
Description: The physical activity intervention will be based on validated behavior change theories aimed at the initiation and long-term maintenance of physical activity.~Participants will be referred to specialists in Adapted Physical Activity for a 6-month program. Exercise sessions will include aerobic exercise and muscle strengthening exercises. Participants will participate in one supervised sessions per week. They will receive instructions for exercising on their own on the other days in order to reach physical activity guidelines. They will also receive instructions and tips to limit sedentary behavior and increase their physical activity throughout the day.~Participants will benefit from an initial consultation with a dietitian and 4 follow-up visits. The follow-up visits will be either group-based or individual, based on participants choice and availabilities. Dietary recommendations will be based on public health guidelines in France aimed at eating a healthy, balanced diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle (physical activity and diet) and Sleep intervention
Description: Participants will benefit from the physical activity and diet intervention detailed above and the following sleep intervention. Participants will fill out an online sleep diagnostic tool includes validated sleep questionnaires (Pittsburgh Sleep Quality Index, Epworth sleepiness scale, Insomnia Severity Index, Berlin questionnaire, Horne and Ostberg questionnaire).~Participants will also log their sleep habits in a 14-day sleep diary. Based on the sleep specialists' review of the results of the questionnaires, sleep diary and analysis of sleep-wake patterns, participants who require further exploration will be referred to a sleep specialist for a consultation and if necessary the appropriate treatment for their sleep disorder.~All participants in this group will benefit from an individualized sleep hygiene intervention. They will benefit from a baseline interview and 3 follow-up visits.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health education intervention
Description: Participants randomized to the control group will benefit from a health education intervention in order to limit deception bias.
Study: NCT06546787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSYCHOTHERAPY
Description: IPT, was prepared by the researcher who completed the interpersonal relations psychotherapy training.The first interview will be conducted face-to-face in the offices of Koç University Faculty of Nursing. Subsequent sessions will be conducted via Zoom according to the availability of the patients included in the study. The day and time of the interviews will be planned according to the availability of the patients before the interviews. A total of 12 interviews are planned to be conducted with a patient for 40-60 minutes each. Interview intervals will be organized as once a week.
Study: NCT05177757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
Study: NCT06058442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10-15 capsules of placebo per day - over 6 months
Study: NCT06335797

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Senna Tab
Description: Senna 8.6mg two tablets per day post operative day 1 and and if needed, then continue on the same dose regiment until post operative day 5.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dulcolax Suppositories
Description: Dulcolax 1 suppository to be placed rectally on the evening of post operative day 1 and if needed, then continue using the same dose regiment until the post operative day 5.
Study: NCT05114005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation
Description: Rhythmically-entrained sensorimotor activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based Exercise
Description: This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hr training (i.e., endurance, resistance, and sensorimotor) performed 2x per week
Study: NCT06570798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Intravenous (IV) Infusion
Study: NCT06532812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor Infiltrating Lymphocytes (TIL) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study: NCT05320835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV, HCV and overdose prevention
Description: HIV, HCV and overdose prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV, HCV and overdose prevention
Description: HIV, HCV and overdose prevention
Study: NCT06138509

Intervention type: OTHER
Intervention: Dosage of serotonin and metabolites
Description: The dosages of serotonin and its metabolites will be performed by the INSERM U1016 unit at Cochin Institute.

Intervention type: OTHER
Intervention: Dosage of serotonin and metabolites
Description: The dosages of serotonin and its metabolites will be performed by the INSERM U1016 unit at Cochin Institute.

Intervention type: OTHER
Intervention: Blood parameters
Description: The characterization of blood parameters : complete blood count (CBC), reticulocytes, C-reactive protein (CRP), iron studies (ferritin, serum iron, transferrin and transferrin saturation), hemoglobin electrophoresis, erythropoietin, will be added using standard methods at the Necker hematology laboratory if not carried out as part of the routine care.

Intervention type: OTHER
Intervention: Blood parameters
Description: The characterization of blood parameters : complete blood count (CBC), reticulocytes, C-reactive protein (CRP), iron studies (ferritin, serum iron, transferrin and transferrin saturation), hemoglobin electrophoresis, erythropoietin, will be added using standard methods at the Necker hematology laboratory if not carried out as part of the routine care.
Study: NCT06501014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy-Experimental Group
Description: Patients will be asked to watch the exercises before doing them.For each exercise, patients will first watch the relevant video and do the exercise after the video ends.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercises-Control Group
Description: Patients will be asked to perform exercises that are described verbally and/or shown through pictures.
Study: NCT06355258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troxerutin
Description: Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + low molecular weight heparin
Description: 2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troxerutin + low molecular weight heparin
Description: 2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Study: NCT06253637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab plus chemotherapy according to the national treatment program
Description: Daratumumab is a human IgG1қ monoclonal antibody that binds with high affinity to a unique epitope on CD38, a transmembrane glycoprotein which is expressed in several hematological malignancies including multiple myeloma (MM) and ALL. Daratumumab induces lysis of CD38-expressing tumor cells by several mechanisms. Intravenous daratumumab has been approved first as a single agent and then in combinations in the MM setting and in AL amyloidosis.~The activity of daratumumab in ALL is being explored in the DELPHINUS trial, in which the drug was combined with chemotherapy in pediatric and young adult patients with relapsed/refractory T-cell ALL or lymphoblastic lymphoma (LL).~In the present trial, daratumumab will be administered to adult Very high risk T-lineage ALL weekly in induction and early consolidation (C1-C2), and the first day of each of the following intensive cycles up to C8.
Study: NCT06646406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient letter and clinician communication
Description: Single mailing to patients from practice with a reminder that the influenza and COVID-19 vaccines are due, and monthly emailing to the patients' clinicians with information about how to make a strong recommendation for those vaccines
Study: NCT05184569

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Verdiperstat
Description: Oral, extended release (ER) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdiperstat
Description: Oral, extended release (ER) tablet
Study: NCT06570798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: SC Injection